Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27357615 | 0.74 | MAPT (0.41) | EPHX1MEN1FAAHMAPK1KMT2A | |
| SCHEMBL4141679 | 0.73 | DNM1 (0.53) | EPHX1DNM1TLR2NAAACES2 | |
| SCHEMBL36377 | 0.72 | RAB9A (0.42) | DNM1TLR2MAPK1 | |
| SCHEMBL8639866 | 0.71 | DNM1 (0.50) | EPHX1DNM1TLR2NAAACES2 | |
| SCHEMBL9730119 | 0.70 | ACE2 (0.43) | DNM1PPARGPPARANAAACES2 | |
| SCHEMBL9730955 | 0.70 | ACE2 (0.43) | DNM1PPARGPPARANAAACES2 | |
| SCHEMBL9730313 | 0.70 | ACE2 (0.43) | DNM1PPARGPPARANAAACES2 | |
| SCHEMBL9783913 | 0.69 | PLA2G2C (0.53) | EPHX1TLR2MEN1FAAHMAPK1 | |
| SCHEMBL8431727 | 0.69 | DNM1 (0.44) | EPHX1DNM1TLR2MEN1KMT2A | |
| SCHEMBL5191054 | 0.69 | DNM1 (0.48) | EPHX1DNM1TLR2MEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667492-A2 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-24 | — | — | EP | claimed |
| EP-4615416-A1 | SELF-ASSEMBLING LIPID NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | Ramot at Tel-Aviv University Ltd. (IL) | 2025-09-17 | — | — | EP | claimed |
| EP-3160448-B1 | LIPOSOMAL FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | UNIV RAMOT (IL) | 2025-08-06 | — | — | EP | claimed |
| EP-3303598-B1 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | UNIV RAMOT (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12065664-B2 | Method for treatment of a leukocyte related disease by delivery of nucleic acid molecules to leukocytes using targeted lipid particles | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-08-20 | — | — | US | claimed |
| WO-2024100656-A1 | SELF-ASSEMBLING LIPID NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-05-16 | — | — | WO | claimed |
| EP-4747231-A1 | LIPIDS AND LIPID NANOPARTICLES | Geneditbio Limited (HK) | 2026-05-27 | — | — | EP | disclosed |
| US-12616662-B2 | Lipid particles for nucleic acid delivery and clinical applications of same | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-05 | — | — | US | disclosed |
| EP-4667492-A2 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-24 | — | — | EP | disclosed |
| EP-4615416-A1 | SELF-ASSEMBLING LIPID NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | Ramot at Tel-Aviv University Ltd. (IL) | 2025-09-17 | — | — | EP | disclosed |
| EP-3160448-B1 | LIPOSOMAL FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | UNIV RAMOT (IL) | 2025-08-06 | — | — | EP | disclosed |
| US-20250162978-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2025-05-22 | — | — | US | disclosed |
| EP-3303598-B1 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | UNIV RAMOT (IL) | 2025-03-19 | — | — | EP | disclosed |
| CN-117136074-A | Lipids suitable for nucleic acid delivery | 雷蒙特亚特特拉维夫大学有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230357353-A1 | MAdCAM-1 POLYPEPTIDES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-11-09 | — | — | US | disclosed |
| US-20230201127-A1 | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS OF SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| EP-4153615-A1 | MADCAM-1 POLYPEPTIDES AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153560-A1 | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS OF SAME | Ramot at Tel-Aviv University Ltd. (IL) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022168085-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-08-11 | — | — | WO | disclosed |
| EP-3538515-B1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | UNIV RAMOT (IL) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201127-A1 | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS OF SAME | FABP1, PLTP, AUP1 | EPHX1 4369/4885DNM1 551/4885TLR2 1924/4885 |
| US-20250162978-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | EPHX1 3101/4885DNM1 165/4885TLR2 1560/4885 |
| US-12616662-B2 | Lipid particles for nucleic acid delivery and clinical applications of same | APOB, APOL1, SLC27A1 | EPHX1 4353/4885DNM1 536/4885TLR2 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.